Impact of IFD on duration of intensive chemotherapy
proven/probable, IFD
Compared to patients without IFD, patients with proven/probable and patients with possible IFD had a significantly longer duration of intensive chemotherapy (measured from start of intensive chemotherapy until start of maintenance therapy). The median duration (years; 1. and 3. quartile) of intensive chemotherapy was 0.69 (0.65; 0.73), 0.69 (0.65; 0.74) and 1.17 (1.09; 1.26) in SR, MR, and HR patients without IFD, 0.74 (0.69; 0.77), 0.72 (0.68; 0.82), and 1.26 (1.15; 1.35) in SR, MR and HR patients with possible IFD versus 0.77 (0.72; 0.86), 0.76 (0.71; 0.88) and 1.21 (1.14; 1.37) in SR, MR and HR patients with proven/probable IFD, respectively. The differences between patients with and without IFD were significant for each of the risk groups (SR and MR 